Abstract:The accumulation of extracellular amyloid-beta (Aβ), denoted as senile plaques, and intracellular neurofibrillary tangles (formed by hyperphosphorylated Tau protein) in the brain are two major neuropathological hallmarks of Alzheimer's disease (AD). The current and most accepted hypothesis proposes that the oligomerization of Aβ peptides triggers the polymerization and accumulation of amyloid, which leads to the senile plaques. Several strategies have been reported to target Aβ oligomerization/polymerization. Since it is thought that Aβ levels in the brain and peripheral blood maintain equilibrium, it has been hypothesized that enhancing peripheral clearance (by shifting this equilibrium towards the blood) might reduce Aβ levels in the brain, known as the sink effect. This process has been reported to be effective, showing a reduction in Aβ burden in the brain as a consequence of the peripheral reduction of Aβ levels. Nanoparticles (NPs) may have difficulty crossing the blood-brain barrier (BBB), initially due to their size. It is not clear whether particles in the range of 50-100 nm should be able to cross the BBB without being specifically modified for it. Despite the size limitation of crossing the BBB, several NP derivatives may be proposed as therapeutic tools. The purpose of this review is to summarize some therapeutic approaches based on nanoliposomes using two complementary examples: First, unilamellar nanoliposomes containing Aβ generic ligands, such as sphingolipids, gangliosides or curcumin, or some sphingolipid bound to the binding domain of ApoE; and second, nanoliposomes containing monoclonal antibodies against Aβ. Following similar rationale NPs of poly(lactide-co-glycolide)-poly (ethylene glycol) conjugated with curcumin-derivate (PLGA-PEG-B6/Cur) were reported to improve the spatial learning and memory capability of APP/PS1 mice, compared with native curcumin treatment. Also, some new nanostructures such as exosomes have been proposed as a putative therapeutic and prevention strategies of AD. Although the unquestionable interest of this issue is beyond the scope of this review article. The potential mechanisms and significance of nanoliposome therapies for AD, which are still are in clinical trials, will be discussed.

SSK1‐Loaded Neurotransmitter‐Derived Nanoparticles for Alzheimer's Disease Therapy via Clearance of Senescent Cells

SSK1‐Loaded Neurotransmitter‐Derived Nanoparticles for Alzheimer's Disease Therapy Via Clearance of Senescent Cells (small 26/2024)

A Nanoformulation‐Mediated Multifunctional Stem Cell Therapy with Improved Beta‐Amyloid Clearance and Neural Regeneration for Alzheimer's Disease

Enhanced Nose-to-Brain Delivery of Combined Small Interfering RNAs Using Lesion-Recognizing Nanoparticles for the Synergistic Therapy of Alzheimer's Disease

Nanomaterials-mediated lysosomal regulation: a robust protein-clearance approach for the treatment of Alzheimer’s disease

Nanoliposomes as a Therapeutic Tool for Alzheimer's Disease

Endo/Lysosome‐Escapable Delivery Depot for Improving BBB Transcytosis and Neuron Targeted Therapy of Alzheimer's Disease

“Cascaded Rocket” Nanosystems with Spatiotemporal Separation for Triple‐Synergistic Therapy of Alzheimer's Disease

A Reactive Oxygen Species‐Responsive Targeted Nanoscavenger to Promote Mitophagy for the Treatment of Alzheimer's Disease

Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model

Highly BBB-permeable nanomedicine reverses neuroapoptosis and neuroinflammation to treat Alzheimer's disease

Dual-functional Nanoparticles for Precise Drug Delivery to Alzheimer’s Disease Lesions: Targeting Mechanisms, Pharmacodynamics and Safety

Neuroprotective Nanoscavenger Induces Coaggregation of Β-Amyloid and Facilitates Its Clearance in Alzheimer’s Disease Brain

Gm1-Modified Lipoprotein-Like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer'S Disease

Cholinergic Neuron Targeting Nanosystem Delivering Hybrid Peptide for Combinatorial Mitochondrial Therapy in Alzheimer?s Disease

Microenvironment Modulating Nanogels by Shiitake-derived Lentinan and a Reactive Oxygen Species Scavenging Conjugated Polymer for the Treatment of Alzheimer’s Disease

Angiopep-2 modified dual drug-loaded liposomes with brain targeting functionality mitigate Alzheimer's disease-related symptoms in APP/PS-1 mice

Therapeutic Nanosweepers Promote Β-Amyloid Removal from the Brain for Alzheimer's Disease Treatment

Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease.

Aβ42 and ROS Dual-targeted Multifunctional Nanocomposite for Combination Therapy of Alzheimer’s Disease

A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer's disease